Search research articles
Contact Us
Filters
Showing results (51-60 of 121) with videos related to
Page
of 13
Sort By:
Neuropharmacology
|
October 18, 2019
Brain-penetrant PQR620 mTOR and PQR530 PI3K/mTOR inhibitor reduce huntingtin levels in cell models of HD
Elisabeth Singer, Carolin Walter, Doriano Fabbro, et al.
Biochimica Et Biophysica Acta
|
November 20, 2009
Extended kinase profile and properties of the protein kinase inhibitor nilotinib
Paul W Manley, Peter Drueckes, Gabriele Fendrich, et al.
Mini Reviews in Medicinal Chemistry
|
March 23, 2004
Imatinib (STI571) resistance in chronic myelogenous leukemia: molecular basis of the underlying mechanisms and potential strategies for treatment
Sandra W Cowan-Jacob, Valerie Guez, Gabriele Fendrich, et al.
Cancer Research
|
May 17, 2008
Phosphorylation regulates transcriptional activity of PAX3/FKHR and reveals novel therapeutic possibilities
Ralf Amstutz, Marco Wachtel, Heinz Troxler, et al.
Journal of Medicinal Chemistry
|
December 6, 2011
7,8-dichloro-1-oxo-β-carbolines as a versatile scaffold for the development of potent and selective kinase inhibitors with unusual binding modes
Kilian Huber, Laurent Brault, Oleg Fedorov, et al.
Acta Crystallographica. Section D, Biological Crystallography
|
December 14, 2006
Structural biology contributions to the discovery of drugs to treat chronic myelogenous leukaemia
Sandra W Cowan-Jacob, Gabriele Fendrich, Andreas Floersheimer, et al.
Chemistry & Biology
|
May 5, 2004
Synthesis and target identification of hymenialdisine analogs
Yongqin Wan, Wooyoung Hur, Charles Y Cho, et al.
ACS Medicinal Chemistry Letters
|
October 18, 2019
Preclinical Development of PQR514, a Highly Potent PI3K Inhibitor Bearing a Difluoromethyl-Pyrimidine Moiety
Chiara Borsari, Denise Rageot, Florent Beaufils, et al.
Journal of the American Chemical Society
|
May 11, 2010
Binding or bending: distinction of allosteric Abl kinase agonists from antagonists by an NMR-based conformational assay
Wolfgang Jahnke, Robert M Grotzfeld, Xavier Pellé, et al.
Neuropharmacology
|
August 7, 2018
The novel, catalytic mTORC1/2 inhibitor PQR620 and the PI3K/mTORC1/2 inhibitor PQR530 effectively cross the blood-brain barrier and increase seizure threshold in a mouse model of chronic epilepsy
Claudia Brandt, Petra Hillmann, Andreas Noack, et al.
Page
of 13
Search research articles
Search
Showing results (51-60 of 121) with videos related to
Sort By:
Page
of 13
Neuropharmacology
|
October 18, 2019
Brain-penetrant PQR620 mTOR and PQR530 PI3K/mTOR inhibitor reduce huntingtin levels in cell models of HD
Elisabeth Singer, Carolin Walter, Doriano Fabbro, et al.
Biochimica Et Biophysica Acta
|
November 20, 2009
Extended kinase profile and properties of the protein kinase inhibitor nilotinib
Paul W Manley, Peter Drueckes, Gabriele Fendrich, et al.
Mini Reviews in Medicinal Chemistry
|
March 23, 2004
Imatinib (STI571) resistance in chronic myelogenous leukemia: molecular basis of the underlying mechanisms and potential strategies for treatment
Sandra W Cowan-Jacob, Valerie Guez, Gabriele Fendrich, et al.
Cancer Research
|
May 17, 2008
Phosphorylation regulates transcriptional activity of PAX3/FKHR and reveals novel therapeutic possibilities
Ralf Amstutz, Marco Wachtel, Heinz Troxler, et al.
Journal of Medicinal Chemistry
|
December 6, 2011
7,8-dichloro-1-oxo-β-carbolines as a versatile scaffold for the development of potent and selective kinase inhibitors with unusual binding modes
Kilian Huber, Laurent Brault, Oleg Fedorov, et al.
Acta Crystallographica. Section D, Biological Crystallography
|
December 14, 2006
Structural biology contributions to the discovery of drugs to treat chronic myelogenous leukaemia
Sandra W Cowan-Jacob, Gabriele Fendrich, Andreas Floersheimer, et al.
Chemistry & Biology
|
May 5, 2004
Synthesis and target identification of hymenialdisine analogs
Yongqin Wan, Wooyoung Hur, Charles Y Cho, et al.
ACS Medicinal Chemistry Letters
|
October 18, 2019
Preclinical Development of PQR514, a Highly Potent PI3K Inhibitor Bearing a Difluoromethyl-Pyrimidine Moiety
Chiara Borsari, Denise Rageot, Florent Beaufils, et al.
Journal of the American Chemical Society
|
May 11, 2010
Binding or bending: distinction of allosteric Abl kinase agonists from antagonists by an NMR-based conformational assay
Wolfgang Jahnke, Robert M Grotzfeld, Xavier Pellé, et al.
Neuropharmacology
|
August 7, 2018
The novel, catalytic mTORC1/2 inhibitor PQR620 and the PI3K/mTORC1/2 inhibitor PQR530 effectively cross the blood-brain barrier and increase seizure threshold in a mouse model of chronic epilepsy
Claudia Brandt, Petra Hillmann, Andreas Noack, et al.
Page
of 13